Alnylam Pharmaceuticals
ALNY
#548
Rank
HK$292.56 B
Marketcap
HK$2,260
Share price
2.60%
Change (1 day)
89.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -HK$1.83 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$2.24 Billion. , an increase over its 2023 earnings that were of -HK$2.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -HK$1.84 Billion-24.59%
2023 -HK$2.43 Billion-67.84%
2022 -HK$7.55 Billion36.93%
2021 -HK$5.52 Billion-8.04%
2020 -HK$6 Billion-15.66%
2019 -HK$7.11 Billion12.23%
2018 -HK$6.34 Billion62.91%
2017 -HK$3.89 Billion17.78%
2016 -HK$3.31 Billion43.44%
2015 -HK$2.31 Billion60.69%
2014 -HK$1.44 Billion98.2%
2013 -HK$0.73 Billion
2011 -HK$0.43 Billion27.48%
2010 -HK$0.34 Billion-10.92%
2009 -HK$0.38 Billion95.77%
2008 -HK$0.2 Billion
2006 -HK$0.31 Billion-9.13%
2005 -HK$0.34 Billion34.74%
2004 -HK$0.26 Billion36.79%
2003 -HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-HK$4.67 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$37.15 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$2.02 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$80.57 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.33 Billion-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$106.04 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$61.74 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-HK$2.2 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel